STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients

View/Open

3991086.pdf (136.9Kb)

Author

Srivastava, Raghvendra M

Jie, Hyun-bae

Ferrone, Soldano

Ferris, Robert L

Published Version

https://doi.org/10.1186/2051-1426-1-S1-P175

Metadata

Show full item record

Citation

Srivastava, Raghvendra M, Hyun-bae Jie, Soldano Ferrone, and Robert L Ferris. 2013. “STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients.” Journal for Immunotherapy of Cancer 1 (Suppl 1): P175. doi:10.1186/2051-1426-1-S1-P175. http://dx.doi.org/10.1186/2051-1426-1-S1-P175.

Other Sources

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991086/pdf/

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Citable link to this page

http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407007